Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 2/20 | 0.36 |
| ▸ | ITGAV | P06756 | 18/20 | 0.36 |
| ▸ | ITGB3 | P05106 | 16/20 | 0.36 |
| ▸ | ITGB6 | P18564 | 6/20 | 0.36 |
| ▸ | ITGB5 | P18084 | 5/20 | 0.35 |
| ▸ | ITGB8 | P26012 | 3/20 | 0.35 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL325378 | 0.95 | CXCR4 (0.39) | CXCR4ITGAVITGB3ITGB6ITGB5 | |
| SCHEMBL19544248 | 0.83 | CXCR4 (0.39) | CXCR4ITGAVITGB3ITGB6ITGB5 | |
| SCHEMBL279379 | 0.78 | CXCR4 (0.42) | CXCR4ITGAVITGB3ITGB6ITGB5 | |
| SCHEMBL28728264 | 0.74 | SMN1; SMN2 (0.33) | — | |
| SCHEMBL6060377 | 0.74 | UHRF1 (0.47) | CXCR4ITGAVITGB3ITGB6ITGB5 | |
| SCHEMBL4530325 | 0.74 | ITGAV (0.43) | CXCR4ITGAVITGB3ITGB6ITGB5 | |
| SCHEMBL16668121 | 0.73 | ALDH1A1 (0.37) | ITGAVITGB3 | |
| SCHEMBL16668453 | 0.73 | ALDH1A1 (0.37) | ITGAVITGB3 | |
| SCHEMBL16668842 | 0.72 | PDE10A (0.38) | — | |
| SCHEMBL8354537 | 0.72 | ITGAV (0.41) | CXCR4ITGAVITGB3ITGB6ITGB8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10463653-B2 | Use of ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors | NOVARTIS AG (CH) | 2019-11-05 | — | — | US | disclosed |
| EP-3200786-B1 | USE OF RING-FUSED BICYCLIC PYRIDYL DERIVATIVES AS FGFR4 INHIBITORS | NOVARTIS AG (CH) | 2019-08-28 | — | — | EP | disclosed |
| US-20190231760-A1 | USE OF RING-FUSED BICYCLIC PYRIDYL DERIVATIVES AS FGFR4 INHIBITORS | EVERNOV MEDICINES LIMITED (CN) | 2019-08-01 | — | — | US | disclosed |
| US-20190076412-A1 | USE OF RING-FUSED BICYCLIC PYRIDYL DERIVATIVES AS FGFR4 INHIBITORS | EVERNOV MEDICINES LIMITED (CN) | 2019-03-14 | — | — | US | disclosed |
| US-20180185341-A1 | USE OF RING-FUSED BICYCLIC PYRIDYL DERIVATIVES AS FGFR4 INHIBITORS | NOVARTIS PHARMA AG (CH) | 2018-07-05 | — | — | US | disclosed |
| EP-3060563-B1 | RING-FUSED BICYCLIC PYRIDYL DERIVATIVES AS FGFR4 INHIBITORS | NOVARTIS AG (CH) | 2018-05-02 | — | — | EP | disclosed |
| US-9896449-B2 | Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors | NOVARTIS AG (CH) | 2018-02-20 | — | — | US | disclosed |
| EP-3200786-A1 | USE OF RING-FUSED BICYCLIC PYRIDYL DERIVATIVES AS FGFR4 INHIBITORS | Novartis AG (CH) | 2017-08-09 | — | — | EP | disclosed |
| US-20170066766-A1 | Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors | NOVARTIS AG (CH) | 2017-03-09 | — | — | US | disclosed |
| US-9533988-B2 | Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors | NOVARTIS AG (CH) | 2017-01-03 | — | — | US | disclosed |
| EP-3060563-A1 | RING-FUSED BICYCLIC PYRIDYL DERIVATIVES AS FGFR4 INHIBITORS | Novartis AG (CH) | 2016-08-31 | — | — | EP | disclosed |
| US-20160102092-A1 | Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors | NOVARTIS AG (CH) | 2016-04-14 | — | — | US | disclosed |
| WO-2016054483-A1 | USE OF RING-FUSED BICYCLIC PYRIDYL DERIVATIVES AS FGFR4 INHIBITORS | NOVARTIS AG (CH) | 2016-04-07 | — | — | WO | disclosed |
| US-9266883-B2 | Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors | NOVARTIS AG (CH) | 2016-02-23 | — | — | US | disclosed |
| US-20150119385-A1 | Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors | NOVARTIS AG (CH) | 2015-04-30 | — | — | US | disclosed |
| WO-2015059668-A1 | RING-FUSED BICYCLIC PYRIDYL DERIVATIVES AS FGFR4 INHIBITORS | NOVARTIS AG (CH) | 2015-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180185341-A1 | USE OF RING-FUSED BICYCLIC PYRIDYL DERIVATIVES AS FGFR4 INHIBITORS | FGFR4, FGFR3, FGFR1 | CXCR4 800/4885ITGAV 2734/4885ITGB3 1802/4885 |
| US-20190076412-A1 | USE OF RING-FUSED BICYCLIC PYRIDYL DERIVATIVES AS FGFR4 INHIBITORS | FGFR4, FGFR1, FGFR3 | CXCR4 1000/4885ITGAV 3554/4885ITGB3 2647/4885 |
| US-20150119385-A1 | Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors | FGFR4, FGFR1, FGFR3 | CXCR4 1107/4885ITGAV 3994/4885ITGB3 3351/4885 |
| US-20160102092-A1 | Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors | FGFR4, FGFR1, FGFR3 | CXCR4 1107/4885ITGAV 3994/4885ITGB3 3351/4885 |
| US-20170066766-A1 | Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors | FGFR4, FGFR1, FGFR3 | CXCR4 1107/4885ITGAV 3994/4885ITGB3 3351/4885 |
| US-20190231760-A1 | USE OF RING-FUSED BICYCLIC PYRIDYL DERIVATIVES AS FGFR4 INHIBITORS | FGFR4, FGFR3, FGFR1 | CXCR4 800/4885ITGAV 2734/4885ITGB3 1802/4885 |
| US-10463653-B2 | Use of ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors | FGFR4, FGFR1, FGFR3 | CXCR4 1000/4885ITGAV 3554/4885ITGB3 2647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.